Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Mesoblast Ltd. (NASDAQ: MESO).

Full DD Report for MESO

You must become a subscriber to view this report.


Recent News from (NASDAQ: MESO)

Mesoblast's Trial Data In AGVHD: An IOMachine Runthrough
When I think of Mesoblast ( MESO ), the negatives I have are: one, this company is based outside US so there’s that much less scrutiny, two, the hyperbole surrounding stem cells, as a Seeking Alpha contributor put it two years ago, and three, these serial accusations of trial data manip...
Source: SeekingAlpha
Date: September, 03 2018 08:52
Mesoblast misses on revenue
Mesoblast (NASDAQ: MESO ): Q4 GAAP EPS of -$0.05. Revenue of $1.7M (+198.2% Y/Y) misses by $1.19M . Press Release More news on: Mesoblast, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: August, 30 2018 00:50
Mesoblast (MESO) CEO Dr. Silviu Itescu on Q4 2018 Results - Earnings Call Transcript
Mesoblast (MESO) Q4 2018 Results Earnings Conference Call August 29, 2018 06:00 PM ET Executives Dr. Silviu Itescu - Chief Executive Officer Josh Muntner - Chief Financial Officer Analysts Mark Breidenbach - Oppenheimer Jason Kolbert - H. C. Wainwright Tanushree Jain - Be...
Source: SeekingAlpha
Date: August, 29 2018 23:28
Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights
MELBOURNE, Australia and NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today reported strong financial results and provided operational highlights for the fourth quarter and full-year ended June 30, 2018 (FY2018). Key financial results for the 12...
Source: GlobeNewswire
Date: August, 29 2018 18:55
Mesoblast provides update on transaction with Tasly Pharmaceutical Group
Mesoblast Limited (NASDAQ: MESO )  enters into an investment agreement as well as a development and collaboration agreement with Tasly Pharmaceutical Group to commercialize cell therapies for cardiovascular diseases in China. More news on: Mesoblast, Healthcare stocks news, ...
Source: SeekingAlpha
Date: August, 29 2018 07:12

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-174.044.004.15044.0074,528
2018-12-144.384.12264.384.0843,066
2018-12-134.594.374.594.287754,840
2018-12-124.124.19914.294.0042,404
2018-12-114.234.184.254.0071,932

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-179,48739,49424.0214Cover
2018-12-1411,50114,96676.8475Short
2018-12-1315,41622,11669.7052Short
2018-12-124,85916,95928.6515Cover
2018-12-113,54923,54915.0707Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MESO.


About Mesoblast Ltd. (NASDAQ: MESO)

Logo for Mesoblast Ltd. (NASDAQ: MESO)

Mesoblast is developing a series of high margin, off the shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.

 

Contact Information

 

 

Current Management

  • Silviu Itescu / CEO
  • Paul Rennie / COO
  • Jenni Pilcher / CFO
  • Julie Meldrum / Director, Corp. Comm.

Current Share Structure

  • Market Cap: $298,933,370 - 05/17/2018
  • Issue and Outstanding: 280,425,300 - 07/20/2011

 


Recent Filings from (NASDAQ: MESO)

Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: August, 31 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 31 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 19 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 05 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 28 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 22 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 20 2018

 

 


Daily Technical Chart for (NASDAQ: MESO)

Daily Technical Chart for (NASDAQ: MESO)


Stay tuned for daily updates and more on (NASDAQ: MESO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MESO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MESO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MESO and does not buy, sell, or trade any shares of MESO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/